Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

QurAlis

QurAlis?uq=kiHouaul
2016 FOUNDED
PRIVATE STATUS
1-10 EMPLOYEES
Early Stage VC LATEST DEAL TYPE
3 INVESTORS
Description

Owner and operator of a bio-pharmaceutical company intended to discover and develop potential new therapeutics for ALS. The company's therapeutics development include development of precision medications that can effectively cure three different forms of ALS with known disease mechanisms which include: a transformative device to remove toxic proteins; a drug that mediates overactive neurons and prevents them from dying; and a drug that restores a dysfunctional waste clearance system in cells, enabling doctors to successfully cure ALS.

Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Therapeutic Devices
Pharmaceuticals
Primary Office
  • 179 Sidney Street
  • Cambridge, MA 02139
  • United States

+1 (617) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore QurAlis’s full profile, request a free trial.

QurAlis Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC 23-Feb-2018 Completed Generating Revenue
To view this company’s complete deal history including valuation and funding, request access »

QurAlis Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Alexandria Venture Investments Corporate Venture Capital Minority 000 0000 000000 0
Amgen Ventures Corporate Venture Capital Minority 000 0000 000000 0
MP Healthcare Venture Management Venture Capital Minority 000 0000 000000 0

QurAlis Executive Team (4)

Name Title Board
Seat
Contact
Info
Kasper Roet Ph.D Co-Founder & Chief Executive Officer
Kevin Eggan Ph.D Co-Founder
Clifford Woolf Ph.D Co-Founder
Jonathan Fleming Co-Founder